← Leaderboards
Katharine June Bar
University Of Pennsylvania
$15,418,177
Attributed
$24,398,911
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,213,990 · 12
By mechanism
R01$11,863,929 · 4
P01$9,655,654 · 3
U01$6,685,272 · 1
P30$2,677,725 · 2
R37$891,410 · 1
R21$440,000 · 1
Top collaborators
- Michael R Betts5 shared
- Tricia Helen Burdo5 shared
- Beatrice H Hahn5 shared
- Rebecca Marie Lynch4 shared
- Mirko Paiardini3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- George M Shaw$56,045,759
- Mirko Paiardini$32,628,549
- Michael R Betts$25,350,826
- Dennis Larry Kolson$16,900,832
- Wade H Berrettini$18,086,963
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralVirusSimian Human Immunodeficiency VirusCellsHiv-1TissuesInfectionViral ReservoirKineticsPlasmaInterruptionDesignViral ReboundAntiretroviral TherapyResponseClinical TrialsVariantBar CodesPreventionNonhuman PrimateAntibodiesPreventAutologousPhenotype
Grant awards (40)
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1$1,849,302
U01 · FY2025 · AI · contact PI
Therapeutic vaccination to boost autologous neutralizing antibodies for ART free HIV Control$891,410
R37 · FY2025 · AI · contact PI
Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiation$840,170
R01 · FY2025 · AI · contact PI
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound$812,498
R01 · FY2025 · AI · contact PI
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing$696,272
R01 · FY2025 · MH · contact PI
Virus & Reservoirs Core$336,575
P30 · FY2025 · AI · contact PI
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1$1,927,304
U01 · FY2024 · AI · contact PI
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing$932,056
R01 · FY2024 · MH · contact PI
Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiation$825,084
R01 · FY2024 · AI · contact PI
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound$812,498
R01 · FY2024 · AI · contact PI
Virus & Reservoirs Core$372,592
P30 · FY2024 · AI · contact PI
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1$1,427,237
U01 · FY2023 · AI · contact PI
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing$936,026
R01 · FY2023 · MH · contact PI
Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiation$880,331
R01 · FY2023 · AI · contact PI
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound$812,498
R01 · FY2023 · AI · contact PI
Virus & Reservoirs Core$349,742
P30 · FY2023 · AI · contact PI
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1$1,481,429
U01 · FY2022 · AI · contact PI
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing$970,435
R01 · FY2022 · MH · contact PI
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound$812,498
R01 · FY2022 · AI · contact PI
Virus & Reservoirs Core$371,400
P30 · FY2022 · AI · contact PI
Immunological Strategies to Modulate SIV Rebound Following ART Interruption$1,497,359
P01 · FY2021 · AI
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing$1,133,540
R01 · FY2021 · MH · contact PI
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound$812,291
R01 · FY2021 · AI · contact PI
Virus & Reservoirs Core$372,727
P30 · FY2021 · AI · contact PI
Project #1 Bar and Shaw$359,724
P01 · FY2021 · AI · contact PI
Immunological Strategies to Modulate SIV Rebound Following ART Interruption$1,510,883
P01 · FY2020 · AI
Virus & Reservoirs Core$372,933
P30 · FY2020 · AI · contact PI
Project #1 Bar and Shaw$318,901
P01 · FY2020 · AI · contact PI
Immunological Strategies to Modulate SIV Rebound Following ART Interruption$1,541,832
P01 · FY2019 · AI
Virus & Reservoirs Core$501,756
P30 · FY2019 · AI · contact PI
Project #1 Bar and Shaw$341,067
P01 · FY2019 · AI · contact PI
Immunological Strategies to Modulate SIV Rebound Following ART Interruption$1,614,482
P01 · FY2018 · AI
Project #1 Bar and Shaw$399,176
P01 · FY2018 · AI · contact PI
Immunological Strategies to Modulate SIV Rebound Following ART Interruption$1,650,523
P01 · FY2017 · AI
Project #1 Bar and Shaw$421,707
P01 · FY2017 · AI · contact PI
Viral and Immune Dynamics of Rebound Viremia after VRC01 Administration$200,000
R21 · FY2016 · AI · contact PI
Viral and Immune Dynamics of Rebound Viremia after VRC01 Administration$240,000
R21 · FY2015 · AI · contact PI
The HIV-1 and HCV Transmission Bottleneck in Chinese Injection Drug Users$190,778
R01 · FY2015 · DA · contact PI
The HIV-1 and HCV Transmission Bottleneck in Chinese Injection Drug Users$196,954
R01 · FY2014 · DA · contact PI
The HIV-1 and HCV Transmission Bottleneck in Chinese Injection Drug Users$200,000
R01 · FY2013 · DA · contact PI